1. Home
  2. STKS vs CING Comparison

STKS vs CING Comparison

Compare STKS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

N/A

Current Price

$1.99

Market Cap

74.3M

ML Signal

N/A

CING

Cingulate Inc.

N/A

Current Price

$7.85

Market Cap

74.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STKS
CING
Founded
2004
2012
Country
United States
United States
Employees
N/A
13
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
74.9M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
STKS
CING
Price
$1.99
$7.85
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$4.38
$31.33
AVG Volume (30 Days)
14.8K
313.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$673,344,000.00
N/A
Revenue This Year
$23.94
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
102.35
N/A
52 Week Low
$1.70
$3.20
52 Week High
$5.19
$7.92

Technical Indicators

Market Signals
Indicator
STKS
CING
Relative Strength Index (RSI) 42.25 67.38
Support Level $1.89 $3.58
Resistance Level $2.65 $7.92
Average True Range (ATR) 0.12 0.50
MACD -0.01 0.06
Stochastic Oscillator 7.69 95.37

Price Performance

Historical Comparison
STKS
CING

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: